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Background & aims: Low levels of serum 25-hydroxy vitamin D (25(OH)D) are common in type 2 diabetic
patients and cause several complications particularly, in postmenopausal women due to their senile and
physiological conditions. This study aimed to assess the effects of vitamin D-fortiﬁed low fat yogurt on
glycemic status, anthropometric indexes, inﬂammation, and bone turnover in diabetic postmenopausal
women.
Methods: In a randomized, placebo-controlled, double-blind parallel-group clinical trial, 59 post-
menopausal women with type 2 diabetes received fortiﬁed yogurt (FY; 2000 IU vitamin D in 100 g/day)
or plain yogurt (PY) for 12 weeks. Glycemic markers, anthropometric indexes, inﬂammatory, and bone
turnover markers were assessed at baseline and after 12 weeks.
Results: After intervention, in FY group (vs PY group), were observed: signiﬁcant increase in serum
25(OH)D and decrease of PTH (stable values in PY); signiﬁcant improvement in serum fasting insulin,
HOMA-IR, HOMA-B, QUICKI, and no changes in serum fasting glucose and HbA1c (signiﬁcant worsening
of all indexes in PY); signiﬁcant improvement in WC, WHR, FM, and no change in weight and BMI (stable
values in PY); signiﬁcant increase of omentin (stable in PY) and decrease of sNTX (signiﬁcant increase in
PY). Final values of glycemic markers (except HbA1c), omentin, and bone turnover markers signiﬁcantly
improved in FY group compared to PY group. Regarding ﬁnal values of serum 25(OH)D in FY group,
subjects were classiﬁed in insufﬁcient and sufﬁcient categories. Glycemic status improved more signif-
icantly in the insufﬁcient rather than sufﬁcient category; whereas the other parameters had more
amelioration in the sufﬁcient category.
Conclusions: Daily consumption of 2000 IU vitamin D-fortiﬁed yogurt for 12 weeks improved glycemic
markers (except HbA1c), anthropometric indexes, inﬂammation, and bone turnover markers in post-
menopausal women with type 2 diabetes.
Trial registration: www.irct.ir (IRCT2013110515294N1).
© 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.M, fat mass; FY, fortiﬁed yogurt; FSG, fasting plasma glucose; HC, hip circumference; HOMA-IR, homeostasis model
eta cell function; hs-CRP, highly sensitive C-reactive protein; PY, plain yogurt; QUICKI, quantitative insulin sensitivity
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International Diabetes Federation has predicted a rise in the
number of diabetic patients throughout the world from 387 in
2014 to 592 million in 2035. In Iran, 8.43% (more than 4 million) of
adults suffered from type 2 diabetes mellitus (T2DM) [1]. A great
deal of therapeutic expenses is dedicated to diabetes and its
complications throughout the world [2]. Postmenopausal diabetic
women are more vulnerable due to several factors such as aging,
probable co-morbidities such as osteoporosis, and socio-economic
conditions.
It has been demonstrated that there is an inverse association
between serum 25(OH)D levels and the risk of T2DM [3]. Vitamin
D plays an important role in insulin resistance. It also has
modulatory effects on growth and differentiation of cells
involved in immune-response as well as in production of in-
ﬂammatory and anti-inﬂammatory cytokines [4]. Therefore,
vitamin D deﬁciency is associated with autoimmune and in-
ﬂammatory diseases like diabetes and metabolic syndrome.
Vitamin D status is deﬁned on the basis of serum concentrations
of 25-hydroxy vitamin D (25(OH)D) as deﬁcient i.e.<50 nmol/l
(20 ng/ml), insufﬁcient i.e. 50e74 nmol/l (21e29 ng/ml), and
sufﬁcient i.e.>75 nmol/l (30 ng/ml) [5].
The major source of vitamin D in human is cutaneous syn-
thesis. Factors such as exposure duration, season, latitude, aging,
skin pigmentation, and continuous usage of sunscreens may
affect vitamin D synthesis. People also receive vitamin D from
foodstuffs such as oily ﬁsh, ﬁsh liver oil, wild mushrooms, and
egg yolk, which are the richest sources of vitamin D but some of
these foods are not part of the usual intake in many countries.
The average intake of vitamin D varies from one country to
another, due to the differences in dietary patterns and food
fortiﬁcation rights. This intake seems to be higher in the coun-
tries fortifying foodstuffs [6]. In Iran, fortiﬁcation of foods with
vitamin D is not customary. According to the latest advice from
Institute of Medicine, a recommended dietary allowance (RDA) of
600 IU/day of vitamin D is needed for ages 1e70 y to provide at
least serum 25(OH)D of 50 nmol/l [7]. The Endocrine Society
recommended 600 IU/day based on bone health and muscle
function protection; however, it is unknown whether the
mentioned dose is enough to supply all the potential non skeletal
functions of vitamin D [5]. The Society has also stated that
consistent daily intake of at least 1500e2000 IU/day is needed to
raise serum 25(OH)D above 75 nmol/l; hence it is necessary to
improve vitamin D intakes via supplementation or food
fortiﬁcation.
High prevalence of vitamin D deﬁciency or insufﬁciency
among Iranian population [8] and lack of accessible vitamin D-
fortiﬁed foodstuffs warrants conducting scientiﬁc-based studies
to introduce suitable staple foods for vitamin D fortiﬁcation.
Recently, some clinical trials have been carried out in Iran on the
effect of vitamin D fortiﬁed foods, like Persian yogurt drink
(Doogh; consists in plain yogurt, water, and salt), milk, and or-
ange juice [9,10]. This study aimed to assess the effects of vitamin
D-fortiﬁed low fat yogurt on glycemic control, anthropometric
indexes, inﬂammation, and bone turnover in diabetic post-
menopausal women. Yogurt could be a good choice for vitamin D
fortiﬁcation due to extensive consumption among Iranian people
and also an appropriate replacement for milk in subjects who are
not able to consume it. Moreover, unlike Doogh (1.6 g/100 g fat
and 380 mg/100 g Na) or sugary juices, low-fat yogurt (1.4 g/
100 g fat and 65 mg/100 g Na) is safe for those who suffer from
diseases like hypertension or diabetes.2. Methods
2.1. Study design and participants
This single center study was a randomized, placebo-controlled,
double-blind parallel-group clinical trial on diabetic post-
menopausal women registered at Isfahan Endocrine and Meta-
bolism Research Center. To calculate the sample size, suggested
formula for parallel-design randomized controlled trial was used
based on a ¼ 0.05, 90% power, and a standardized effect size of
D ¼ 1 in NTX [11] as a key variable. We reached to 22 participants
per group.
We studied 148 medical records of diabetic womenwho did not
use insulin. The diagnosis of T2DMwas based onWHO criteria [12].
Among the records, postmenopausal women who had not menses
for at least 12 months were selected. The cases were enrolled in the
study if they met these inclusion criteria: (i) not taking vitamin D,
calcium, or omega-3 supplements within the past 3 months before
the intervention, (ii) not taking drugs which have obvious inter-
action with vitamin D or inﬂuence its metabolism i.e. corticoste-
roids or estrogens, (iii) baseline serum 25(OH)D < 125 nmol/l, and
(iv) not having history of malignancy, renal failure, liver, endocri-
nologic, or inﬂammatory disorders. All subjects had to spend a 3
weeks run-in period during which they were instructed by a die-
titian to follow a weight-maintenance diet according to American
Diabetes Association guidelines [13]. After that period, subjects
who had weight changes were excluded and the others were
randomly divided to 2 groups. The equivalent amounts of dairy
products were replaced by 1 serving (100 g) per day of low-fat
yogurt in their diet. During the intervention, the exclusion criteria
were: (i) any change in type or dosage of oral anti-diabetic drugs or
usage of insulin, (ii) intake of vitamin D, calcium or omega-3 sup-
plements, and (iii) disobedience to the study protocol.
2.2. Study protocol
The study protocol was approved by the Ethical Committee of
Research, Isfahan University of Medical Sciences on 19 July 2013
(registration number: 192015). The study protocol and its progress
were recorded at www.irct.ir (registration ID:
IRCT2013110515294N1). At ﬁrst, the study protocol and objectives
were fully explained to each subject and then written informed
consent was obtained from all participants.
2.3. Randomization and blinding
Study's enrolled patients underwent permuted block randomi-
zation. Each block had permuted, even-numbered, randomly
varying block sizes with 1:1 allocation ratio. The block sizes were
concealed till the end of the study. Subjects were randomly allo-
cated to the ‘FY’ (received vitamin D-fortiﬁed low fat yogurt, con-
taining 2000 IU vitamin D in 100 g) or ‘PY’ (received plain low fat
yogurt without additive) treatment groups. The random sequence
was generated by an investigator uninvolved in recruiting subjects.
Both participants and investigators were blinded to the content of
interventions.
2.4. Outcome measurements
The project was launched at late fall (December 2013), going on
during the winter, and ﬁnished after 12 weeks of intervention in
the middle of March, 2014 in order to minimize the cutaneous
synthesis of vitamin D. Participants consumed one serving of low
Table 1
General characteristics of participants at baseline.
Variables FYa (n ¼ 30) PYb (n ¼ 29) Pc
Age (year) 57.8 ± 5.5 56.8 ± 5.7 0.47
BMI (kg/m2) 28.00 ± 0.82 29.30 ± 0.72 0.23
FM (%) 36.80 ± 0.70 37.21 ± 0.76 0.68
Diabetes duration (year) 9.3 ± 5.3 8.8 ± 4.8 0.70
Menopausal duration (year) 8.1 ± 6.2 8 ± 4.5 0.94
Physical activity (MET h1 d1) 23.4 ± 1.8 23.3 ± 2.0 0.94
Sun exposure (minute/day) 24.7 ± 11.0 23 ± 11.2 0.84
25-hydroxy vitamin D (nmol/l) 62.23 ± 4.52 62.72 ± 4.27 0.94
All presented values are means ± SEs.
a Fortiﬁed yogurt group.
b Plain yogurt group.
c Denote signiﬁcance of between group changes (t-test).
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intervention period. Blood samples were taken at the beginning
and at the end of the intervention, between 7:30 and 8:30 AM,
while subjects were fast for more than 12 h. The sera samples were
isolated and kept at 80 C prior to analyses.
2.5. Laboratory measurements
Fasting serum glucose (FSG), total cholesterol (TC), low density
lipoprotein (LDL), high density lipoprotein (HDL), and triglycerides
(TG) were measured using enzymatic methods. Serum highly sen-
sitive C-reactive protein (hs-CRP) was determined by immuno-
turbidimetric assay. The commercial kits from Pars Azmun Inc.
(Tehran, Iran) were used to perform the tests. Serum insulin levels
were determined by radioimmunoassay (ADVIA Centaur CP, USA).
HbA1c was separated by ion-exchange chromatography and
measured by a colorimetric method (DS5 Analyzer, England).
Serum parathyroid hormone (PTH) (DiaMetra, Milan, Italy), bone
alkaline phosphatase (sBAP), N-terminal type-1 collagen (sNTX),
and omentin (Eastbiopharm Company, USA), and serum 25(OH)D
(LDS Ltd., USA) were determined by ELISA.
Homeostasis model assessment of insulin resistance (HOMA-
IR), Homeostasis model assessment of b cell function (HOMA-B),
and quantitative insulin sensitivity check index (QUICKI) were
calculated according to the suggested equations. Anthropometric
indexes were measured as follows: weight and percentage of body
fat mass (FM) were measured by using an electrical body analyzer
(Body composition Analyzer, ioi 353, JAWONMEDICAL, Korea) with
light clothes and without shoes. Height was measured with a sta-
diometer to the nearest of 0.1 cm. BMI was calculated as weight in
kg/(height inmeter)2. Ameasuring tape to the nearest of 0.1 cmwas
used to assess waist circumference (WC) and hip circumference
(HC). WC was measured at the midpoint of lower rib and iliac crest
when the patients were at the end of breathing out. HC was
measured from where the buttocks protrude the most.
2.6. Yogurt manufacture
Preparation and fortiﬁcation of low fat yogurt were performed
in Allas Dairy Products Company (Allas Dairy, Isfahan, Iran). Energy,
protein, fat, Na, and Ca contents of 100 g low fat yogurt were
57 kcal, 3 g, 1.4 g, 65 mg, and 150 mg, respectively. Vitamin D used
for fortiﬁcation was a powder “Dry Vitamin D3 100 SD/S” (con-
tained 100,000 IU Vitamin D3 per gram, suitable for fortiﬁcation of
water-based foods, product code: 5010950.304; DSM Nutritional
Products Ltd., Basel, Switzerland). Concentrations of vitamin D and
its stability in yogurt had been checked at the ﬁrst day of produc-
tion, after 1, and 2 weeks of refrigerated storage. The results
demonstrated that vitamin D was stable during the product shelf-
life.
Participants were visited once aweek to assess their compliance
and receive 7 packets of low-fat yogurt for consumption. They were
instructed to tick the consumption calendar, every day. The calen-
dar was planned to make sure that subjects will consume the
yogurt regularly. They were also asked to return the empty packets
on their next visit.
Demographic data, duration of daily sun exposure, durations of
diabetes and menopause, concomitant diseases, drugs, and smok-
ing habits were collected using questionnaires.
2.7. Dietary intake and physical activity assessment
Dietary intake and physical activity of the participants were
monitored by an expert dietitian at the beginning, weeks 3, 6, 9,
and at the end of the intervention period (including a weekend)using a 24-h recall questionnaire. To derive energy and nutrients,
all dietary data were converted to gram and entered to Nutritionist
4 software (based on United States Department of Agriculture
(USDA) food composition table and modiﬁed for Iranian foods).
Then the average of 5 day-dietary recalls was expressed as dietary
intake (Table S1). Metabolic equivalent (MET) value for each
physical activity [15] was multiplied by the duration of the activity
(MET h1 d1), and the average of 5 dayephysical activity recalls
was reported (Table 1).
2.8. Statistical analyses
Quantitative data were expressed as mean ± SE, while qualita-
tive data as number and percentage. Normality of studied variables
was evaluated using KolmogoroveSmirnov test and QeQ plot.
Positively skewed data were subjected to logarithmic trans-
formation. Within group analyses were conducted using paired
samples t-test based on change from baseline. Between group an-
alyses were conducted using multivariate analysis of covariance
(MANCOVA) in different models. In the crude model, the 2 groups
were compared based on the ﬁnal values of the variables studied; in
the model 1, adjustment was made for the baseline values, while in
the model 2 the adjustment was made, in addition to baseline
values, also for age, diabetes duration, menopausal duration,
physical activity, energy, and protein.We presented only the results
of models 1 and 2. Also, chi-square test was used for comparing the
qualitative data between 2 studied groups.
2.9. Subgroup analysis
Subjects who received FY were divided, after the completion of
the study, in three subgroups (deﬁcient, insufﬁcient, sufﬁcient)
according to the baseline values of serum 25(OH)D concentrations,
and in two subgroups (insufﬁcient, sufﬁcient) according to the ﬁnal
values of serum 25(OH)D concentrations. Data of these groups were
analyzed, for within-groups differences, with the same methods
utilized previously, while between-groups differences were studied
with MANCOVA adjusted for baseline values of variables and for
age, dietary energy, and protein intake during the study.
3. Results
Ninety three postmenopausal diabetic women were enrolled at
ﬁrst. Among them, 25 patients who did not met the inclusion
criteria were kept out. We also excluded 4 women who had high
serum 25(OH) D (>125 nmol/l). The remaining 64 participants were
randomly divided in to the 2 parallel groups after run-in period.
Five women were excluded during the intervention (week 3). All
the remaining 59 participants completed the project (Fig. 1). The
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activity, and sun exposure did not differ signiﬁcantly between 2
groups (Table 1). The percentages of patients taking oral anti-
diabetic drugs were as follows: metformin, 66.6% in FY group and
65.5% in PYgroup; glitazone, 10% in FYgroup and 10.4% in PYgroup;
oral agent combination, 23.3% in FY group and 24.1% in PY group.
The average dietary intakes also did not signiﬁcantly differ between
the 2 groups except for protein (Table S1), which is considered as a
confounder in the analyses.
3.1. Vitamin D status and serum PTH
At start, the 79.7% of subjects was vitamin D deﬁcient or insuf-
ﬁcient. At the end of the study period, the vitamin D status of the FY
group was substantially improved: serum 25(OH)D signiﬁcantly
(P > 0.001) increased (Table 3), and no more subject was deﬁcient;
the percentage of subjects with a sufﬁcient vitamin D status
increased from 20% to 50% (Table 2), and their ﬁnal serum 25(OH)D
was 107.86 ± 5.77 nmol/l, while ﬁnal serum 25(OH)D in the
insufﬁcient group was 65.8 ± 1.32 nmol/l. Otherwise, vitamin D
status in PY group got worse: serum 25(OH)D, even if not signiﬁ-
cantly, decreased (Table 3), and the percentage of sufﬁcient subjects
lowered from 20.7% to 3.4% (Table 2). Serum PTH decreased
signiﬁcantly in FY group (P ¼ 0.01), while it did not signiﬁcantly
change in PY group (P ¼ 0.129; Table 3).
3.2. Glycemic status
Compared to baseline, serum fasting insulin, and the indexes of
insulin resistance, secretion and sensitivity improved after inter-
vention in FY group, (but FSG and HbA1c did not signiﬁcantlyFig. 1. Flowchart of study dchange), while all the glycemic control markers (except HOMA-B)
worsened in PY group (Table 3). Final values of all glycemic in-
dexes (except HbA1c) were signiﬁcantly improved in comparison
with the PY group (Table 4).3.3. Lipid proﬁle
Comparing to baseline values, TG decreased signiﬁcantly in FY
group (P ¼ 0.046), while cholesterol, LDL and HDL did not change
signiﬁcantly (Table 3). Final values of TG, cholesterol, and HDL did
not show signiﬁcant differences between FY and PY groups both in
model 1 and model 2 (Table 4). However, marginally signiﬁcant
differences were observed between the 2 groups in ﬁnal values of
LDL (model 1: P ¼ 0.056; model 2: P ¼ 0.053).3.4. Anthropometric indexes
Final values of waist circumference (WC), waist to hip ratio
(WHR), and fat mass (FM) signiﬁcantly decreased in FY group
compared to baseline (P < 0.001), whereas weight, BMI, and hip
circumference (HC) did not change signiﬁcantly (Table 3). There
were signiﬁcant differences between the 2 groups in ﬁnal values of
WC, WHR, BMI, and FM in model 1 and model 2 (Table 4).3.5. Blood pressure
Systolic and diastolic blood pressure did not change signiﬁcantly
in FY and PY group compared to baseline (Table 3). There were also
no signiﬁcant differences in ﬁnal values of blood pressure compo-
nents between FY and PY groups (Table 4).esign and participants.
Table 2
Distribution of participants based on vitamin D status before and after the intervention.
Group Before intervention After intervention
Deﬁcienta Insufﬁcientb Sufﬁcientc Pf Deﬁcienta Insufﬁcientb Sufﬁcientc Pf
PYd [n (%)] 10(34.5) 13(44.8) 6(20.7) 0.915 12(41.4) 16(55.2) 1(3.4) <0.001
FYe [n (%)] 9(30) 15(50) 6(20) 0(0) 15(50) 15(50)
Total [n (%)] 19(32.2) 28(47.5) 12(20.3) 12(20.3) 31(52.5) 16(27.1)
a Participant with serum 25(OH)D < 50 nmol/l.
b Participant with serum 25(OH)D between 50 and 75 nmol/l.
c Participant with serum 25(OH)D > 75 nmol/l.
d Plain yogurt.
e Fortiﬁed yogurt.
f Denotes the signiﬁcance of differences in vitamin D categories between 2 groups before and after the intervention (chi-square test).
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hs-CRP decreased in FY group compared to baseline but the
result was not statistically signiﬁcant (P ¼ 0.074), while omentin
increased signiﬁcantly in this group (P ¼ 0.001; Table 3). Table 4
represents that ﬁnal values of hs-CRP were signiﬁcantly different
between the 2 groups (model 1, P ¼ 0.037); however, when other
confounders were controlled, ﬁnal values of hs-CRP did not show
statistically signiﬁcant difference between the groups (model 2,
P ¼ 0.197). Final values of omentin were signiﬁcantly different be-
tween the groups (model 1: P¼ 0.001; model 2: P¼ 0.018; Table 4).
3.7. Bone turnover
sBAP and sNTX decreased in FY group compared to baseline
values, but only the decrement of sNTX was statistically signiﬁcantTable 3
Comparison of baseline and ﬁnal values of study variables.
Variable FYa group
Before After
25(OH)D (nmol/l) 62.23 ± 4.5 86.83 ± 4.87
PTH (pg/ml) 54.86 ± 2.7 46.70 ± 2.38
Glycemic markers
FSG (mg/dl) 168.80 ± 4.48 166.67 ± 5.45
Fasting serum insulin (mU/l) 7.71 ± 1.23 5.17 ± 0.46
HOMA-IR 3.23 ± 0.50 2.13 ± 0.20
HOMA-B 95.28 ± 16.00 64.27 ± 5.98
QUICKI 0.331 ± 0.004 0.348 ± 0.004
HbA1c (%) 7.16 ± 0.23 7.24 ± 0.22
Lipid proﬁle
Triglycerides (mg/dl) 133.56 ± 10.05 129.10 ± 9.80
Cholesterol (mg/dl) 182.23 ± 8.49 180.77 ± 8.65
LDL (mg/dl) 108.00 ± 6.70 107.33 ± 6.66
HDL (mg/dl) 52.93 ± 1.96 55.93 ± 1.87
Anthropometric indexes
Weight (kg) 67.10 ± 2.06 66.54 ± 2.13
BMI (kg/m2) 28.00 ± 0.82 27.84 ± 0.80
WC (cm) 97.60 ± 1.48 96.54 ± 1.46
HC (cm) 102.20 ± 1.24 102.03 ± 1.24
WHR 0.95 ± 0.006 0.94 ± 0.006
FM (%) 36.80 ± 0.70 33.91 ± 1.03
Blood pressure markers
SBP (mm Hg) 128.31 ± 1.40 128.97 ± 1.28
DBP (mm Hg) 75.12 ± 3.50 75.45 ± 3.51
Inﬂammatory markers
hs-CRP (mg/l) 1.32 ± 0.19 0.98 ± 0.04
Omentin (ng/l) 88.69 ± 9.54 122.84 ± 15.12
Bone markers
sBAP (IU/l) 84.13 ± 12.60 78.46 ± 11.07
sNTX (nmol/l) 57.15 ± 5.95 36.63 ± 5.38
All presented values are means ± SEs.
a Fortiﬁed yogurt.
b Plain yogurt.
c P values denote signiﬁcance of within-group changes (paired t-test).(sBAP: P¼ 0.210; sNTX: P < 0.001; Table 3). In PYgroup, ﬁnal values
of sBAP and sNTX increased; however, the increment of sBAP was
not statistically signiﬁcant (sBAP: P ¼ 0.107; sNTX: P ¼ 0.001;
Table 3). Final values of sBAP and sNTX were signiﬁcantly different
between FY and PY groups, both in model 1 and in model 2
(Table 4).
3.8. Multivariate analyses
Multivariate analyses (Wilks Lambda) demonstrated that
glycemic status, anthropometric measurements, inﬂammation,
and bone turnover were signiﬁcantly improved in FY group
compared to PY group after adjustment for baseline values
(model 1) or even after controlling the other confounders (model
2). Moreover, lipid proﬁle and blood pressure did not signiﬁ-
cantly improved (Table 4).PYb group
Pc Before After Pc
<0.001 62.72 ± 4.27 56.13 ± 2.89 0.270
0.010 53.58 ± 3.15 56.75 ± 3.13 0.129
0.177 167.48 ± 2.78 170.62 ± 2.66 0.004
0.029 8.78 ± 1.08 11.20 ± 1.04 0.032
0.020 3.58 ± 0.42 4.72 ± 0.44 0.016
0.039 109.70 ± 14.53 135.02 ± 13.08 0.074
0.001 0.327 ± 0.005 0.312 ± 0.005 0.018
0.744 7.08 ± 0.30 7.58 ± 0.23 0.029
0.046 144.96 ± 11.81 149.21 ± 14.92 0.961
0.296 189.96 ± 7.48 191.34 ± 7.15 0.597
0.475 106.20 ± 5.86 120.34 ± 10.31 0.035
0.074 49.03 ± 1.62 50.28 ± 1.77 0.217
0.257 69.30 ± 1.87 69.42 ± 2.04 0.799
0.352 29.30 ± 0.72 29.56 ± 0.76 0.087
<0.001 96.45 ± 1.24 96.54 ± 1.23 0.226
0.063 102.24 ± 1.40 102.14 ± 1.40 0.319
<0.001 0.94 ± 0.004 0.94 ± 0.004 0.290
<0.001 37.22 ± 0.76 37.90 ± 0.77 0.248
0.484 128.50 ± 1.50 129.30 ± 1.63 0.473
0.547 81.93 ± 0.94 81.90 ± 1.17 0.958
0.074 1.07 ± 0.05 1.21 ± 0.10 0.201
0.001 99.96 ± 14.73 93.79 ± 14.55 0.289
0.210 78.05 ± 9.70 87.68 ± 7.69 0.107
<0.001 52.73 ± 6.67 59.82 ± 6.77 0.001
Table 4
Effects of vitamin D fortiﬁed yogurt on glycemic markers, lipid proﬁle, anthropometric indexes, blood pressure, inﬂammatory, and bone turnover markers.
Variable Model 1a Model 2b
FYc group PYd group Pe FYc group PYd group Pe
PTH (pg/ml)* 46.26 ± 1.88 57.21 ± 1.91 <0.001 46.31 ± 2.04 57.15 ± 2.07 0.001
Glycemic markers <0.001** 0.001**
FSG (mg/dl) 166.39 ± 1.06 170.90 ± 1.08 0.005 166.60 ± 1.17 170.68 ± 1.19 0.026
Fasting serum insulin (mu/l) 5.44 ± 0.74 10.92 ± 0.75 <0.001 5.27 ± 0.81 11.01 ± 0.83 <0.001
HOMAIR 2.47 ± 0.31 4.60 ± 0.31 <0.001 2.18 ± 0.34 4.66 ± 0.35 <0.001
HOMA-B 67.37 ± 9.18 131.81 ± 9.35 <0.001 64.10 ± 10.05 134.27 ± 10.25 <0.001
QUICKI 0.346 ± 0.004 0.314 ± 0.004 <0.001 0.35 ± 0.00 0.31 ± 0.005 <0.001
HbA1c (%) 7.17 ± 0.17 7.65 ± 0.18 0.063 7.25 ± 0.17 7.58 ± 0.18 0.227
Lipid proﬁle 0.127** 0.115**
Triglycerides (mg/dl) 133.41 ± 6.40 144.74 ± 6.50 0.270 136.50 ± 6.47 141.54 ± 6.60 0.802
Cholesterol (mg/dl) 185.06 ± 2.10 186.90 ± 2.13 0.553 184.60 ± 2.25 187.37 ± 2.30 0.425
LDL (mg/dl) 106.90 ± 5.84 120.80 ± 5.95 0.056 106.27 ± 6.15 121.44 ± 6.27 0.053
HDL (mg/dl) 54.90 ± 1.27 51.35 ± 1.30 0.063 55.08 ± 1.35 51.15 ± 1.38 0.063
Anthropometric indexes <0.001** 0.001**
Weight (kg) 67.50 ± 0.47 68.44 ± 0.48 0.180 67.25 ± 0.50 68.70 ± 0.51 0.069
BMI (kg/m2) 28.38 ± 0.15 29.00 ± 0.15 0.008 28.32 ± 0.16 29.06 ± 0.17 0.006
WC (cm) 95.99 ± 0.16 97.12 ± 0.17 <0.001 95.95 ± 0.18 97.16 ± 0.18 <0.001
HC (cm) 102.08 ± 009 102.09 ± 0.10 0.901 102.04 ± 0.10 102.13 ± 0.11 0.580
WHR 0.940 ± 0.002 0.951 ± 0.002 <0.001 0.940 ± 0.002 0.951 ± 0.002 <0.001
FM (%) 34.13 ± 0.61 37.68 ± 0.62 <0.001 34.22 ± 0.60 37.59 ± 0.62 0.001
Blood pressure markers 0.956** 0.983**
SBP (mm Hg) 129.14 ± 0.97 129.09 ± 0.98 0.969 129.26 ± 1.02 128.97 ± 1.03 0.854
DBP (mm Hg) 78.75 ± 0.60 78.50 ± 0.61 0.767 78.65 ± 0.66 78.59 ± 0.68 0.949
Inﬂammatory markers <0.001** 0.014**
hs-CRP (mg/l) 0.97 ± 0.08 1.22 ± 0.08 0.037 1.01 ± 0.08 1.18 ± 0.08 0.197
Omentin (ng/l) 129.23 ± 8.07 87.18 ± 8.21 0.001 123.21 ± 8.00 93.41 ± 8.15 0.018
Bone markers <0.001** <0.001**
sBAP (IU/l) 76.23 ± 4.40 89.99 ± 4.45 0.032 75.54 ± 4.62 90.71 ± 4.70 0.033
sNTX (nmol/l) 34.73 ± 2.62 61.78 ± 2.67 <0.001 34.44 ± 2.85 62.09 ± 2.90 <0.001
Variables are after intervention measurements and represented “estimated marginal means” ± SEs.
* Results were obtained from ANCOVA for between group comparisons based on after intervention-values (adjustment was made for baseline values).
**P values are resulted from MANCOVA, Wilks Lambda tests.
a Adjusted for baseline values.
b Adjusted for baselines, age, physical activity, diabetes duration, menopausal duration, energy, and protein intake.
c Fortiﬁed yogurt.
d Plain yogurt.
e P values are resulted from MANCOVA for between group comparisons based on after intervention values.
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3.9.1. Subgroup analyses based on baseline values of serum 25(OH)
D
Regarding the baseline value of serum 25(OH)D in participants
of FY group, we recognized 3 subgroups as deﬁcient, insufﬁcient,
and sufﬁcient; the increment of serum 25(OH)D in the subgroups
was 31.33, 21.2, and 23 nmol/l, respectively. Serum PTH decreased
in the subgroups, but the result was statistically signiﬁcant only in
deﬁcient subgroup (Table 5). It was also the only marker which was
signiﬁcantly different among the subgroups (P ¼ 0.019; Table S2).
Insulin indexes improved in each of the subgroups compared to
baseline values, but just participants of the insufﬁcient subgroup
showed statistically signiﬁcant results. However, the result for
QUICKI was also signiﬁcant in deﬁcient subgroup. FSG and HbA1c
did not signiﬁcantly change in each of the subgroups. Final values of
lipid and blood pressuremarkers did not signiﬁcantly change in the
subgroups (Table 5).
Considering the anthropometric indexes, participants in deﬁ-
cient subgroup showed signiﬁcant decrease in ﬁnal value of WC
compared to baseline, while in the insufﬁcient subgroup, ﬁnal
values of WC, WHR, and FM signiﬁcantly decreased. In sufﬁcient
subgroup, statistically signiﬁcant reduction was observed just for
the ﬁnal value of FM (Table 5).
The inﬂammatory markers did not signiﬁcantly changed
compared to baselines in the subgroups except for omentin which
increased signiﬁcantly in the sufﬁcient subgroup (Table 5).Considering the bonemarkers, sBAP did not signiﬁcantly change
in the subgroups, but sNTX signiﬁcantly decreased in the deﬁcient
and insufﬁcient subgroups (Table 5).
Results of MANCOVA tests represented that glycemic markers,
lipid proﬁle, anthropometric indexes, inﬂammatory markers, and
bone markers did not differ signiﬁcantly among the subgroups
(Table S2).
3.9.2. Subgroup analyses based on ﬁnal values of serum 25(OH)D
Regarding ﬁnal values of 25(OH)D in FYgroup, participants were
categorized as insufﬁcient or sufﬁcient subgroups at the end of the
intervention. Within subgroup analysis showed that serum PTH
signiﬁcantly decreased in both insufﬁcient and sufﬁcient categories
(Table 6) but the result of ANCOVA test represented no statistically
signiﬁcant difference between categories (Table S3).
Fasting serum insulin, HOMA-IR, and QUICKI signiﬁcantly
decreased in the insufﬁcient subgroup. FSG and HOMA-B decreased
in this subgroup but the results were not statistically signiﬁcant. In
the sufﬁcient subgroup, glycemic markers did not signiﬁcantly
change compared to baseline (Table 6).
As shown in Table 6, ﬁnal values of lipid markers in each of the
subgroups did not signiﬁcantly change compared to baseline except
for HDL which showed a small but signiﬁcant increase in the suf-
ﬁcient subgroup. Blood pressure markers also, did not signiﬁcantly
change in the subgroups.
Considering the changes in anthropometric indexes, ﬁnal values
of WC andWHR decreased signiﬁcantly both in the insufﬁcient and
Table 5
Comparison of initial and ﬁnal values of study variables based on categorized baseline vitamin D status in fortiﬁed yogurt group.
Variable Deﬁcienta (n ¼ 9) Insufﬁcientb (n ¼ 15) Sufﬁcientc (n ¼ 6)
Before After Pd Before After Pd Before After Pd
25(OH)D (nmol/l) 36.55 ± 3.68 67.88 ± 2.41 <0.001 62.00 ± 1.64 83.20 ± 5.97 0.001 101.33 ± 6.21 124.33 ± 5.34 0.016
PTH (pg/ml) 57.33 ± 6.02 43.77 ± 3.66 0.013 56.60 ± 3.76 52.26 ± 3.38 1.00 46.83 ± 3.46 37.16 ± 3.98 0.142
Glycemic markers
FSG (mg/dl) 169.84 ± 6.37 169.58 ± 5.46 0.498 167.87 ± 4.13 167.89 ± 3.30 0.095 166.33 ± 6.34 168.75 ± 6.09 0.882
Fasting serum insulin (mU/l) 9.54 ± 1.91 7.53 ± 0.86 0.159 7.73 ± 1.00 4.87 ± 2.08 0.033 5.11 ± 1.02 4.08 ± 1.01 0.247
HOMA-IR 4.01 ± 0.762 3.14 ± 0.372 0.123 3.81 ± 0.401 3.09 ± 0.447 0.024 4.92 ± 0.459 2.05 ± 0.801 0.776
HOMA-B 116.23 ± 24.81 91.90 ± 10.46 0.194 82.88 ± 13.49 51.38 ± 11.14 0.048 65.37 ± 11.25 59.85 ± 12.08 0.546
QUICKI 0.321 ± 0.006 0.342 ± 0.006 0.035 0.322 ± 0.005 0.332 ± 0.005 0.015 0.332 ± 0.006 0.333 ± 0.010 0.065
HbA1c (%) 6.82 ± 0.36 7.16 ± 0.249 0.739 7.58 ± 0.264 7.71 ± 0.234 0.923 6.50 ± 0.328 7.07 ± 0.732 0.763
Lipid proﬁle
Triglycerides (mg/dl) 115.00 ± 13.35 114.78 ± 13.34 0.799 147.33 ± 14.51 139.13 ± 14.29 0.059 127.00 ± 28.62 125.50 ± 28.50 0.394
Cholesterol (mg/dl) 168.77 ± 13.09 166.55 ± 13.55 0.190 188.00 ± 12.75 187.64 ± 13.47 0.828 188.00 ± 21.46 185.33 ± 18.90 0.375
LDL (mg/dl) 98.11 ± 10.34 96.00 ± 10.33 0.167 114.80 ± 11.13 115.26 ± 10.92 0.751 105.83 ± 11.08 104.50 ± 11.10 0.408
HDL (mg/dl) 48.55 ± 2.55 53.66 ± 2.65 0.108 56.73 ± 3.22 57.53 ± 3.13 0.756 50.00 ± 2.81 55.33 ± 3.66 0.104
Anthropometric indexes
Weight (kg) 68.12 ± 4.26 67.12 ± 4.57 0.278 68.22 ± 2.94 66.84 ± 2.96 0.078 64.26 ± 4.15 64.43 ± 4.22 0.104
BMI (kg/m2) 28.45 ± 1.62 28.83 ± 1.65 0.303 28.32 ± 1.19 27.90 ± 1.10 0.096 26.54 ± 1.60 26.21 ± 1.62 0.218
WC(cm) 100.24 ± 3.58 98.74 ± 3.70 0.027 96.98 ± 1.41 96.33 ± 1.40 0.01 95.18 ± 3.87 93.78 ± 3.53 0.074
HC (cm) 103.38 ± 2.90 103.06 ± 2.89 0.175 102.28 ± 1.44 102.20 ± 1.42 0.469 100.23 ± 3.01 100.05 ± 3.09 0.324
WHR 0.968 ± 0.011 0.958 ± 0.014 0.052 0.948 ± 0.006 0.942 ± 0.006 0.002 0.948 ± 0.006 0.937 ± 0.018 0.093
FM (%) 36.66 ± 1.52 34.44 ± 2.50 0.147 36.90 ± 0.797 34.44 ± 1.15 0.024 36.66 ± 2.09 32.00 ± 2.39 0.016
Blood pressure markers
SBP (mm Hg) 128.72 ± 2.82 130.00 ± 2.32 0.582 128.26 ± 1.64 126.93 ± 1.56 0.063 127.83 ± 4.36 132.50 ± 3.59 0.070
DBP (mm Hg) 63.42 ± 10.83 62.49 ± 10.82 0.602 80.53 ± 1.09 80.33 ± 1.14 0.802 79.16 ± 2.00 80.50 ± 2.92 0.318
Inﬂammatory markers
hs-CRP 1.62 ± 0.441 1.11 ± 1.01 0.309 1.01 ± 0.030 0.890 ± 0.056 0.106 1.66 ± 0.692 1.00 ± 0.094 0.333
Omentin (ng/l) 102.42 ± 25.35 117.36 ± 30.08 0.210 78.59 ± 8.65 117.51 ± 19.86 0.042 91.84 ± 21.36 144.39 ± 39.72 0.118
Bone markers
sBAP (IU/l) 77.54 ± 21.01 70.96 ± 23.33 0.455 81.27 ± 17.86 77.06 ± 13.18 0.566 101.19 ± 35.15 93.02 ± 31.22 0.255
sNTX (nmol/l) 60.24 ± 10.63 31.46 ± 7.67 0.001 56.48 ± 9.02 38.71 ± 8.95 <0.001 54.21 ± 13.51 39.17 ± 11.18 0.267
All presented values are means ± SEs.
a Serum 25(OH)D < 50 nmol/l.
b Serum 25(OH)D between 50 and 75 nmol/l.
c Serum 25(OH)D > 75 nmol/l.
d P values denote signiﬁcance of within-group changes (paired t-test).
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icant just in the sufﬁcient subgroup (Table 6). It was also the only
index which was signiﬁcantly different between the subgroups
(P ¼ 0.009; Table S3).
Omentin signiﬁcantly increased in the insufﬁcient and sufﬁcient
subgroups compared to baseline values. The decrement of hs-CRP
in both subgroups was not statistically signiﬁcant (Table 6).
In the insufﬁcient subgroup, sBAP did not signiﬁcantly change
compared to baseline, but it decreased signiﬁcantly in the sufﬁcient
subgroup. sNTX decreased signiﬁcantly in the subgroups compared
to baselines (Table 6).
According to the MANCOVA test (Wilks Lambda), glycemic sta-
tus, lipid proﬁle, anthropometric measurements, inﬂammation,
and bone turnover did not signiﬁcantly differ between insufﬁcient
and sufﬁcient subgroup (Table S3).4. Discussion
There is no consensus on the threshold for optimal level of
serum 25(OH)D. Most experts believe that for maximizing healthy
functions of vitamin D, a serum concentration of 25(OH)
D > 75 nmol/l is needed. To obtain the mentioned value, regular
intake of 1500e2000 IU/day vitamin D is recommended [5]. In this
study, approximately 80% of the participants in each group were
vitamin D deﬁcient or insufﬁcient. Daily consumption of 2000 IU/
d vitamin D fortiﬁed low-fat yogurt for 12 weeks signiﬁcantly
increased the serum 25(OH)D concentration in the group treated,
and raised the percentage of subjects considered sufﬁcient as
vitamin D status (serum 25(OH)D > 75 nmol/l) from 20% to 50%.The use of such high dosage in our study is reasonable due to the
fact that some previous studies with lower dosages reported
inconclusive results [14]. The mentioned dose is regarded safe due
to the current knowledge [5].
The content of fat and Na in low-fat yogurt used in this study
was 1.4 g/100 g and 65 mg/100 g, respectively. Regarding the age
and cardiovascular risks of the patients participated in this study, it
seems that fortiﬁcation of low-fat yogurt is reasonable compared to
Doogh which contain higher levels of fat (1.6 g/100 g) and Na
(380 mg/100 g).
No differences in baseline values of serum 25(OH)D and dura-
tion of sun exposure were observed among groups; therefore,
improvement in vitamin D status of the subjects is due to
intervention.
Observational studies revealed inverse association between
serum 25(OH)D and incidence of T2DM [3]. A meta-analysis of
prospective observational studies demonstrated a decrease of 58%
in risk of T2DM in the highest quintile of serum 25(OH)D compared
to the lowest [16]. Potential mechanisms for effects of vitamin D on
T2DM are currently recognized. Vitamin D is known to have anti-
inﬂammatory effects through the regulation of inﬂammatory and
anti-inﬂammatory markers. Systemic inﬂammation is also identi-
ﬁed as one of the basic components of T2DM. Furthermore,
pancreatic beta cells have speciﬁc receptors for 1,25(OH)2D, the
active form of vitamin D, whose regulatory effects on insulin
secretion have been reported [17]. Vitamin D also has some bene-
ﬁcial effects on insulin resistance; it may stimulate the expression
of insulin receptors and therefore enhance insulin response to
glucose. It also provides an adequate intracellular cytosolic calcium
Table 6
Comparison of initial and ﬁnal values of study variables based on categorized ﬁnal vitamin D status in fortiﬁed yogurt group.
Variable Insufﬁcienta (n ¼ 15) Sufﬁcientb (n ¼ 15)
Before After Pc Before After Pc
25(OH)D (nmol/l) 47.86 ± 3.86 65.80 ± 1.32 <0.001 76.60 ± 6.36 107.86 ± 5.77 <0.001
PTH (pg/ml) 61.93 ± 4.06 52.00 ± 2.99 0.009 47.80 ± 2.63 41.40 ± 3.24 0.038
Glycemic markers
FSG (mg/dl) 177.53 ± 9.40 172.46 ± 7.55 0.073 160.06 ± 4.90 160.86 ± 4.60 0.559
Fasting serum insulin (mU/l) 9.80 ± 2.32 5.36 ± 0.66 0.047 5.62 ± 0.48 4.96 ± 0.65 0.337
HOMA-IR 4.26 ± 0.91 2.27 ± 0.28 0.027 2.19 ± 0.16 1.98 ± 0.26 0.423
HOMA-B 116.84 ± 30.66 65.07 ± 8.60 0.073 73.71 ± 7.42 63.46 ± 8.61 0.266
QUICKI 0.321 ± 0.007 0.344 ± 0.006 0.002 0.342 ± 0.004 0.351 ± 0.006 0.154
HbA1c (%) 7.40 ± 0.34 7.53 ± 0.35 0.758 6.92 ± 0.32 6.95 ± 0.25 0.910
Lipid proﬁle
Triglycerides (mg/dl) 140.46 ± 14.50 136.93 ± 14.52 0.220 126.66 ± 14.19 121.26 ± 13.35 0.123
Cholesterol (mg/dl) 182.60 ± 14.74 180.33 ± 15.43 0.125 181.86 ± 8.99 181.20 ± 8.46 0.787
LDL (mg/dl) 115.33 ± 12.46 114.33 ± 12.30 0.250 100.66 ± 4.78 100.33 ± 5.04 0.837
HDL (mg/dl) 51.33 ± 2.85 52.53 ± 2.10 0.672 54.53 ± 2.71 59.33 ± 2.90 0.011
Anthropometric indexes
Weight (kg) 67.39 ± 3.54 66.56 ± 3.56 0.306 66.81 ± 2.70 66.53 ± 2.47 0.635
BMI (kg/m2) 28.60 ± 1.43 28.47 ± 1.36 0.624 27.41 ± 0.81 27.21 ± 0.87 0.423
WC(cm) 97.77 ± 2.33 96.73 ± 2.35 0.011 97.42 ± 1.90 96.36 ± 1.83 0.002
HC (cm) 102.17 ± 1.93 102.00 ± 1.90 0.308 102.23 ± 1.65 102.05 ± 1.67 0.070
WHR 0.956 ± 0.007 0.947 ± 0.008 0.017 0.951 ± 0.09 0.942 ± 0.10 0.005
FM (%) 36.19 ± 1.06 35.21 ± 1.45 0.235 37.40 ± 0.93 32.62 ± 1.43 <0.001
Blood pressure markers
SBP (mm Hg) 130.56 ± 1.87 130.26 ± 1.57 0.835 126.06 ± 1.99 127.66 ± 2.03 0.190
DBP (mm Hg) 72.25 ± 6.91 71.71 ± 6.84 0.533 78.00 ± 1.17 79.20 ± 1.24 0.076
Inﬂammatory markers
hs-CRP 1.11 ± 0.05 1.02 ± 0.08 0.380 1.54 ± 0.37 0.94 ± 0.04 0.109
Omentin (ng/l) 90.08 ± 15.45 127.87 ± 23.90 0.055 87.30 ± 11.76 117.81 ± 19.28 0.026
Bone markers
sBAP (IU/l) 72.29 ± 18.41 73.53 ± 16.85 0.866 95.97 ± 17.29 83.39 ± 14.86 0.019
sNTX (nmol/l) 51.11 ± 8.94 31.76 ± 7.78 <0.001 63.20 ± 7.85 41.50 ± 7.48 0.001
All presented values are means ± SEs.
a Serum 25(OH)D between 50 and 75 nmol/l.
b Serum 25(OH)D > 75 nmol/l.
c P values denote signiﬁcance of within-group changes (paired t-test).
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membrane calcium ﬂux [18].
Results of randomized controlled trials about the effects of
vitamin D on glycemic markers are inconsistent. Sugden et al. re-
ported no signiﬁcant changes in glycemic markers after adminis-
tration of 100000 IU single dose of ergocalciferol (vitamin D2) in
diabetic patients, but they found signiﬁcant improvement in insulin
sensitivity in subjects who had a 25(OH)D increase of 11 nmol/l or
more after conducting a post-hoc analysis [4]. Shab-Bidar et al.
showed that glycemic status improved in diabetic patients after 12
weeks consumption of 1000 IU vitamin D-fortiﬁed Doogh [9]. In
our study, insulin functions improved in FY group compared to PY
group. In agreement to our study, results of a previous meta-
analysis demonstrated that vitamin D supplementation did not
reduce HbA1c values [14]. It has to be pointed that some previous
studies [4,19] even with high dosages and longer interventional
period performed on vitamin D deﬁcient patients, did not found
signiﬁcant improvement in glycemic control. Subgroup analyses
based on ﬁnal values of serum 25(OH)D represented more
improvement in glycemic status in the insufﬁcient rather than
sufﬁcient category. More studies are needed to clarify the optimal
levels of 25(OH)D for a good glycemic status.
Results of clinical trials about the effects of vitamin D supple-
mentation on lipid proﬁle are contradicting. Heikkinen et al. re-
ported detrimental effects of 3 y treatment with 300 IU/day vitamin
D on lipid proﬁle in postmenopausal women [20]. Data from
Women's Health Initiative (WHI) study documented that 5 y cal-
cium (1000 mg/day) and vitamin D (400 IU/day) co-
supplementation did not change the lipid proﬁle [21]. Shab-Bidar
et al. reported that 1000 IU vitamin D-fortiﬁed Doogh improvedlipid proﬁle in patients with T2DM [9]. In this study, TG was the
only lipid marker demonstrating small signiﬁcant improvement in
FY group. Subgroup analyses revealed no differences on the lipid
markers between subject in the insufﬁcient and sufﬁcient cate-
gories except for HDL, which improved signiﬁcantly in the subjects
whose serum 25(OH)D levels exceeded 75 nmmol/l.
Previous cross-sectional studies showed that serum 25(OH)D is
inversely associated with obesity and body fat [22]. Regarding the
positive relationship between serum concentration of PTH and
obesity and the role of PTH in increasing lipogenesis and decreasing
lipolysis [23], suppressing effect of vitamin D on serum PTH justiﬁes
its inﬂuence on anthropometric indexes. Vitamin D also decreases
the expression and activity of peroxisome proliferator-activated
receptor-gamma in adipocytes and therefore inhibits adipo-
genesis [24]. We found that 2000 IU vitamin D-fortiﬁed yogurt
improved WC, FM, and BMI speciﬁcally when the levels of serum
25(OH)D reached>75 nmol/l. Nikooyeh et al. also reported similar
results in their study, in which T2DM patients consumed 1000 IU
vitamin D-fortiﬁed Doogh [25]. Weight and HC did not signiﬁcantly
change in our study but Nikooyeh et al. reported signiﬁcant weight
reduction in their trial. In the WHI study, a negligible weight
reduction (0.13 kg during 7 y) was observed in postmenopausal
women received 400 IU vitamin D and 1000 mg calcium per day
[21].
Results of studies about the effects of vitamin D on systolic and
diastolic blood pressure are inconsistent [4,19,25]. The suppressing
effects of vitamin D on renin production and PTH secretion may
control blood pressure [4]. Based on the results of a meta-analysis,
vitamin Dmay control blood pressure in hypertensive subjects [26].
In our study, neither systolic nor diastolic blood pressure were
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not hypertensive.
Anti-inﬂammatory effects of vitamin D have now been recog-
nized. It is believed that 1,25(OH)2D regulates production of in-
ﬂammatory cytokines and modulates the function of granulocyte
and macrophage [27]. Observational studies reported higher levels
of serum hs-CRP in subjects with hypovitaminosis D [28]. In a
recent systematic review of clinical trials, no effect of vitamin D
supplementation on hs-CRP was reported [29]. Neyestati et al. re-
ported amelioration of hs-CRP and plasma ﬁbrinogen concentra-
tions after 12 weeks consumption of 1000 IU fortiﬁed Doogh in
diabetic patients [10]. In our study, ﬁnal values of hs-CRP revealed
no remarkable difference between the 2 groups after adjustment
for confounders. It was assumed that the anti-inﬂammatory effects
of vitamin D are more prominent in severe inﬂammatory condi-
tions [30].
Omentin, a novel adipocytokine derived from visceral adipose
tissue, was found by Yang et al., in 2003. The omentin gene is
located in the 1q22eq23 chromosomal region, which is known to
have link with T2DM. Body of evidence around the inverse asso-
ciation between omentin and obesity, insulin resistance, or
impaired glucose tolerance is increasing [31,32]. Furthermore, it has
been stated that serum omentin levels are lower in post-
menopausal women compared to premenopausal women and also
there is an inverse relationship between serum omentin and bone
turnover markers (sBAP and sNTX) [33]. We demonstrated for the
ﬁrst time the improving effect of vitamin D fortiﬁed low fat yogurt
on serum omentin in postmenopausal women with T2DM.
An inverse association between serum 25(OH)D levels and bone
turnover markers were reported in several studies. Secondary hy-
perparathyroidism may occur in vitamin D deﬁciency which in-
creases bone turnover markers. Furthermore, postmenopausal
women have higher serum concentration of these markers [34]. In
this study, sNTX and sBAP, as bone turnover markers, decreased in
FYgroup after the intervention. The decrement of serum PTH levels
in the FYgroup after the intervention justiﬁes the decreases in bone
turnover markers, whilst the markers ﬁnally increased in the PY
group concurrently with the increment in PTH values. Due to the
higher turnover of bone markers in winter months [34], the
markers increased in PY group, whereas vitamin D-fortiﬁed yogurt
overcame this phenomenon and improved the condition.
We could not show signiﬁcant differences in measured ﬁnal
values of markers and indexes among the subgroups based on
baseline or ﬁnal levels of serum 25 (OH)D. However, based on
baseline serum 25(OH)D, the within subgroup changes were more
favorable in subjects categorized as insufﬁcient. Considering the
ﬁnal levels of serum 25(OH)D, glycemic markers were improved in
the insufﬁcient subgroup, whereas the other improved markers
and indexes were in the sufﬁcient subgroup. It can be concluded
that the serum 25(OH)D might be raised to a certain level to have
beneﬁcial effects. We think that further studies with more partic-
ipants and longer interventional periods are needed to compare the
differences among the subgroups more accurately.
Our different results compared to the results of previous studies
could be due to the following reasons:
- Usage of a fortiﬁed food instead of a pharmacological supplement:
It seems that studies which used fortiﬁed foods obtained more
favorable results than the studies which used pharmacological
supplements. It is possible that fortiﬁed food by itself may in-
ﬂuence the metabolic responses.
- The difference in the baseline serum 25(OH)D of participants: In
this study, about 32% of the participants were vitamin D deﬁ-
cient, whereas in some previous studies approximately most of
the subjects were vitamin D deﬁcient. It is possible that thebaseline levels of serum 25(OH)D may affect the metabolic re-
sponses of the patients.
Limitations of our study are as follows: (i) 12 weeks intervention
might be inadequate to affect long-term markers like HbA1c. (ii)
Seasonal effects may inﬂuence the results of our study speciﬁcally
bone markers. As a result, further long intervention clinical trials
with different doses of vitamin D fortiﬁcation are recommended.
5. Conclusions
Our study demonstrated that 2000 IU vitamin D-fortiﬁed low fat
yogurt could increase the levels of serum 25(OH)D concentration
satisfactorily. Glycemic status, anthropometric indexes, inﬂamma-
tory, and bone turnover markers improved after 12 weeks inter-
vention in postmenopausal women with T2DM. The measured
markers improved when serum 25(OH)D concentrations exceeded
75 nmol/l with the exception of glycemic markers which showed
more improvement in the level of serum 25(OH)D concentrations
between 50 and 75 nmol/l. The desirable compliance of the product
by the subjects suggests that low-fat yogurt could be a good choice
for vitamin D fortiﬁcation in Iran.
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